Tubulis
PVT · PVT·Munich, Germany·Private·Phase 1
Clinical-stage biotech developing next-generation antibody-drug conjugates using proprietary Tub-tag and P5 conjugation platforms for superior stability and efficacy. Being acquired by Gilead Sciences for approximately $3.1B upfront (up to $5B total), announced April 2026.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Tubulis website | Website | May 6, 2026 | 4 |